Legend Biotech (LEGN) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
JPMorgan on Legend Biotech Corp. (LEGN): 'Remain Confident in Carvykti’s Profile Post ODAC Briefing Docs'
March 13, 2024 12:10 PM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "While we expect the FDAs question around the imbalance in early death in CARTITUDE-4 to be taken seriously at Fridays ad com on Carvykti, the data around early deaths show it... More
